Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -42

Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q2 Earnings

AI-generated analysis

πŸ“‰ Becton Dickinson (BDX) reported Q2 revenue of $4.71 billion, a 10.6% decline year-over-year ending March 2026.

πŸ’° Earnings per share were $2.90, slightly below the $3.35 reported in the year-ago quarter.

🎯 Revenue beat the Zacks Consensus Estimate of $4.67 billion by approximately +1.04%.

πŸ“Š EPS exceeded analyst consensus of $2.77 by a surprise of +4.82%.

🩺 Medical Essentials revenue dropped significantly, showing a year-over-year decrease of 40.3% to $1.65 billion.

πŸ”— Connected Care United States revenue reached $840 million against an average estimate of $819.64 million.

🌍 Connected Care International generated $280 million, surpassing the estimated $268.2 million.

πŸ’Š Medication Management Solutions-International revenue grew 12.8% year-over-year to $168 million.

πŸ”ͺ Interventional-Surgery revenue was $411 million, representing a 7.3% increase from last year.

βš–οΈ Interventional-Urology and Critical Care saw reported revenue of $430 million with a 7.5% year-over-year change.

πŸ’‰ Medication Delivery Solutions revenue hit $1.16 billion against an estimated $1.15 billion average.

πŸ“ˆ BioPharma Systems generated $590 million, exceeding the analyst average estimate of $580.75 million.

πŸ›οΈ Overall Connected Care revenue totaled $1.12 billion, compared to a $1.1 billion average estimate.

πŸ“‰ Stock shares fell 7.9% over the past month while the Zacks S&P 500 composite rose 11.4%.

⏸️ BDX currently holds a Zacks Rank of #3 (Hold), suggesting performance in line with the broader market.

Bullish Signals
  • Becton Dickinson's reported revenue of $4.71 billion beat the Zacks Consensus Estimate of $4.67 billion by 1.04%, demonstrating resilience despite a year-over-year decline.
  • The company's EPS surprise was notably strong at +4.82%, as reported earnings of $2.90 significantly exceeded the consensus estimate of $2.77, signaling better underlying profitability than expected.
  • Revenues for Connected Care - Medication Management Solutions - International surged by 12.8% year-over-year to reach $168 million, exceeding analyst estimates.
  • The Interventional - Surgery segment delivered solid growth with a 7.3% year-over-year increase to $411 million, performing slightly above the average analyst estimate.
  • Connected Care - Medication Management Solutions also showed positive momentum, posting a 2.2% year-over-year increase to surpass its consensus revenue expectation.
  • Becton Dickinson successfully beat estimates in multiple segments including BioPharma Systems and Medical Essentials- Medication Delivery Solutions, which met or exceeded average analyst projections.
Risk Factors
  • Total revenue declined 10.6% year-over-year to $4.71 billion, indicating significant headwinds across the business despite segment-level surprises.
  • Earnings per share (EPS) dropped from $3.35 to $2.90, representing a substantial decline in profitability compared to the prior year.
  • Revenue from Medical Essentials fell by 40.3% year-over-year to $1.65 billion, highlighting severe struggles in this specific segment.
  • Shares underperformed significantly with a -7.9% return over the past month versus an +11.4% gain for the S&P 500 composite.
  • The stock currently holds a Zacks Rank of #3 (Hold), signaling neutral to negative sentiment rather than strong upside potential.
Full Analysis
Becton Dickinson (BDX) reported second-quarter financials for the period ending March 2026, posting total revenues of $4.71 billion and earnings per share (EPS) of $2.90. While the revenue figure surpassed analyst consensus by approximately $38 million, representing a slight positive surprise over Wall Street's expectation, the company experienced a significant year-over-year decline. Revenue dropped 10.6% compared to the prior year, and EPS fell from $3.35 to $2.90, even as some business segments grew. The financial performance was mixed across specific product lines, with notable divergence between segments. Medical Essentials revenues contracted sharply by 40.3% year-over-year to reach $1.65 billion, failing to meet analyst estimates. Conversely, Connected Care revenue increased slightly to $1.12 billion, and several interventional surgery segments showed growth; for instance, Interventional-Urology and Critical Care revenues rose 7.5% year-over-year to $430 million. Medication Management Solutions also saw a 12.8% increase internationally, while other connected care and bio-pharma systems segments generally met or beat their respective estimates based on analyst consensus. Following the earnings release, Becton Dickinson shares fell -7.9% over the past month, underperforming the Zacks S&P 500 composite which gained 11.4% during the same period. The current market assessment for the stock is a Zacks Rank #3 (Hold), suggesting expectations are that the stock may perform in line with the broader market in the near term. Analysts note that while top-line metrics like revenue missed significantly year-over-year, specific sub-segments like Connected Care and certain interventional therapies provided positive signals despite the overall headwinds in the medical essentials division.